NCT02319642View on ClinicalTrials.gov

An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044

PHASE3CompletedINTERVENTIONAL

Enrollment

347

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Certolizumab Pegol

Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection

Trial Locations (30)

Unknown

037, Baotou

001, Beijing

002, Beijing

013, Beijing

021, Beijing

025, Beijing

033, Beijing

014, Bengbu

034, Changchun

017, Changsha

019, Changsha

007, Chengdu

012, Chengdu

004, Guangzhou

015, Hangzhou

005, Hefei

008, Heilongjiang

011, Jilin

022, Jinan

031, Kunming

028, Nanjing

009, Shanghai

018, Shanghai

020, Shanghai

030, Shanghai

038, Shijiazhuang

010, Tianjin

006, Wuhan

016, Xi'an

035, Xi'an

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

UCB Pharma SA

INDUSTRY